New drug aims to wake up transplanted kidneys faster
NCT ID NCT07020832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called pegcetacoplan in 320 adults who are getting a kidney transplant from a deceased donor and are at high risk for delayed graft function (when the kidney takes a while to start working). The goal is to see if the drug helps the kidney work sooner and reduces the need for dialysis after transplant. Participants will receive either pegcetacoplan or a placebo, and their kidney function will be tracked for up to a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECEASED DONOR KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, 01323-001, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Can a new drug combo help kidney transplants last longer?
- Ultrasound may fine-tune fluid balance in dialysis patients — a trial puts it to the test
- Dialysis patients may straighten up with In-Chair exercise
- New nerve block may cut opioid use after kidney transplants
- Could pumpkin seed oil ease inflammation in dialysis patients?